There are many cytokines involved in the pathogenesis of osteoporosis. So far IL-33 involvement in osteoporotic patients has not yet been studied. IL-33 is a pro-inflammatory cytokine which mediates several immune functions; its involvement in a wide range of diseases, such as atopic dermatitis, asthma, and rheumatoid arthritis, is now emerging. In view of the crucial role of this cytokine in inflammation and bone remodeling, we measured IL-33 levels in the serum of postmenopausal women with osteoporosis. In 50 postmenopausal osteoporotic patients and 28 healthy postmenopausal control women, serumIL-33 levels were measured by enzyme linked immunosorbent assay. In both patients and controlsthe bone mineral density (BMD) was measured by double-energy X-ray absorptiometry (DXA).Vitamin D, calcium, alkaline phosphatase (ALP),parathyroid hormone (PTH)serum levels, as well as bone turnover markers, such as C-terminal telopeptide of type 1 collagen (CTX) and N-terminal propeptide of type 1 procollagen (P1NP) were also evaluated. In postmenopausal osteoporotic women IL-33 levels were significantly lower compared to healthy controls (3.53 ± 2.45 vs. 13.72 ±5.39 pg/ml; P = 0.009). and positively correlated respectivelywith serum PTH (rho=0.314; P=0.026)and P1NP (rho=0.373; P=0.011)levels, while a statistically significant inverse correlation was observed between serum IL-33 and CTX levels (rho=-0.455; P=0.002).Our results thus suggest that IL-33 represents an important bone-protecting cytokine which may be of therapeutic benefit in treating bone resorption.

Interleukin-33 serum levels in postmenopausal women with osteoporosis

Lia Ginaldi;Massimo De Martinis
;
Maria Maddalena Sirufo;Fedra Ciccarelli;
2019-01-01

Abstract

There are many cytokines involved in the pathogenesis of osteoporosis. So far IL-33 involvement in osteoporotic patients has not yet been studied. IL-33 is a pro-inflammatory cytokine which mediates several immune functions; its involvement in a wide range of diseases, such as atopic dermatitis, asthma, and rheumatoid arthritis, is now emerging. In view of the crucial role of this cytokine in inflammation and bone remodeling, we measured IL-33 levels in the serum of postmenopausal women with osteoporosis. In 50 postmenopausal osteoporotic patients and 28 healthy postmenopausal control women, serumIL-33 levels were measured by enzyme linked immunosorbent assay. In both patients and controlsthe bone mineral density (BMD) was measured by double-energy X-ray absorptiometry (DXA).Vitamin D, calcium, alkaline phosphatase (ALP),parathyroid hormone (PTH)serum levels, as well as bone turnover markers, such as C-terminal telopeptide of type 1 collagen (CTX) and N-terminal propeptide of type 1 procollagen (P1NP) were also evaluated. In postmenopausal osteoporotic women IL-33 levels were significantly lower compared to healthy controls (3.53 ± 2.45 vs. 13.72 ±5.39 pg/ml; P = 0.009). and positively correlated respectivelywith serum PTH (rho=0.314; P=0.026)and P1NP (rho=0.373; P=0.011)levels, while a statistically significant inverse correlation was observed between serum IL-33 and CTX levels (rho=-0.455; P=0.002).Our results thus suggest that IL-33 represents an important bone-protecting cytokine which may be of therapeutic benefit in treating bone resorption.
File in questo prodotto:
File Dimensione Formato  
Ginaldi_et_al-2019-Scientific_Reports.pdf

accesso aperto

Descrizione: articolo principale
Tipologia: Documento in Versione Editoriale
Licenza: Creative commons
Dimensione 1.04 MB
Formato Adobe PDF
1.04 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11697/132213
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 39
  • ???jsp.display-item.citation.isi??? 36
social impact